Navigation Links
Drug Effective Against Heart-Lung Disorder
Date:6/19/2008

Bosentan slowed decline linked to pulmonary arterial hypertension, study found

THURSDAY, June 19 (HealthDay News) -- The drug bosentan reduced clinical decline in patients with early-stage pulmonary arterial hypertension (PAH), Italian researchers report.

PAH is a progressive disease in which increased pulmonary resistance in the lungs causes structural damage to the heart, eventually leading to heart failure and death.

Previous studies have shown that bosentan improves exercise capacity and pulmonary vascular resistance (PVR) and slows clinical decline in patients with later stages of PAH.

This new study included 185 people, ages 12 and over, with early-stage PAH who were divided into two groups. One group received bosentan, and the other group received a placebo. The patients' PVR and distance they could walk in six minutes were measured at the start of the study and again six months later.

After six months, the mean PVR improved at a significant rate for those on bosentan versus those on placebo, wrote Professor Nazzareno Galie, of the Institute of Cardiology at the University of Bologna, and colleagues.

The mean six-minute walk distance also increased 11.2 meters in the bosentan group from 438 meters at baseline, compared to a decrease from 431 meters to 423 meters in the placebo group. However, these changes in distance weren't clinically significant.

Three percent of patients in the bosentan group and 14 percent of those in the placebo group experienced clinical worsening events, such as symptomatic progression of PAH, hospitalization and death. This difference was statistically significant.

Thirteen percent of patients in the bosentan group and 9 percent of those in the placebo group reported serious adverse events. Fainting was the most common adverse event in the bosentan group, and right ventricular failure was the most common in the placebo group.

The findings are in the June 21 issue of The Lancet.

"This study broadens the potential for bosentan as a treatment in pulmonary arterial hypertension, and the evidence presented by (the researchers) should soon be translated into clinical practice," Dr. Neeraj Dhaun and Professor David Webb, Queen's Medical Research Institute, University of Edinburgh, U.K., wrote in an accompanying comment.

More information

The U.S. National Heart, Lung, and Blood Institute has more about PAH.



-- Robert Preidt



SOURCE: The Lancet, news release, June 20, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Build and Maintain an Effective Competitive Intelligence Group
2. Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey
3. HIV Tests Cost-Effective for Some Seniors
4. Effective health messages may yield vaccine compliance among ER workers
5. Effective treatment for sickle cell underused by doctors
6. Effective Communication of Clinical Studies for Maximum Impact
7. Winning Method - Effective Identification and Development of Clinical Investigators
8. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
9. Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis
10. Whole Milk Cheaper, Effective Contrast Agent for GI Scans
11. Tracking Cancer Drugs Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Effective Against Heart-Lung Disorder
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford ... this week. A group of researchers and leaders from Sanford Health were selected ... Medicine and Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, ... The competition will be held at the University of Montana on April 28-May 1. ... the Mississippi River. , In order to qualify, Varize needed to place top seven ...
(Date:4/28/2016)... Angeles, CA (PRWEB) , ... April 28, 2016 , ... ... on its website, cosmetictown.com . The forum section was recently revamped and upgraded ... the latest surgical techniques in use across the country. , According to the senior ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named ... emerging field of biomechatronics, technology that marries human physiology with electromechanics. He continues that ... is also the Founder of BionX , a leader in the field of ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore ... This is unfortunately true. But we toss the baby out with the bathwater when ... provides tips for identifying higher-quality studies and otherwise making better use of education policy ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- TapImmune,Inc. (TPIV), a clinical-stage immune-oncology ... immunotherapeutics and vaccines for the treatment of cancer & metastatic ... Annual Growth Capital Expo to be held on May ... Palace in Las Vegas, Nevada.  The Company presentation will ... by Dr. John N. Bonfiglio a TapImmune ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
Breaking Medicine Technology: